The U.S. Food and Drug Administration has granted Orphan Drug Designation to Lantern Pharma’s LP-284 for the treatment of soft tissue sarcomas. This marks the third orphan designation for the LP-284 program and the sixth overall across the company’s clinical pipeline. The designation represents a significant expansion for LP-284 beyond hematologic malignancies into solid tumors, reflecting its synthetic lethal mechanism that targets DNA repair deficiencies common in adult soft tissue sarcomas.
Lantern Pharma stated that the orphan drug designation supports an accelerated regulatory pathway for LP-284 as the company continues Phase 1 evaluation in B-cell non-Hodgkin lymphomas and advances development in additional rare cancer indications. The company’s proprietary RADR® AI platform integrates hundreds of billions of data points to identify biomarkers, predict drug response, and design smarter clinical trials, which has been instrumental in advancing their oncology pipeline.
The orphan drug designation is particularly important for patients with soft tissue sarcomas, a group of rare cancers that often have limited treatment options. By targeting DNA repair deficiencies through a synthetic lethal approach, LP-284 represents a precision medicine strategy that could benefit specific patient populations with these genetic vulnerabilities. The designation provides Lantern Pharma with certain development incentives, including potential market exclusivity and tax credits for clinical research.
This regulatory milestone comes as Lantern Pharma continues to build its clinical-stage pipeline, which includes LP-184, LP-284, and LP-300, each targeting genomically defined patient populations. The company’s approach leverages artificial intelligence and machine learning to streamline oncology drug development and bring precision therapies to patients. Additional information about Lantern Pharma’s developments is available through their newsroom at https://ibn.fm/LTRN.
The broader implications of this designation extend beyond LP-284’s development timeline. It demonstrates the growing recognition of synthetic lethal approaches in oncology and validates Lantern Pharma’s strategy of using genomic data and AI to identify promising therapeutic targets. As the company advances LP-284 through clinical development, this orphan designation could facilitate more efficient regulatory review and potentially faster access to treatment for patients with soft tissue sarcomas who currently have limited therapeutic options.
This news story relied on content distributed by InvestorBrandNetwork (IBN). Blockchain Registration, Verification & Enhancement provided by NewsRamp™. The source URL for this press release is Lantern Pharma Receives FDA Orphan Drug Designation for LP-284 in Soft Tissue Sarcomas.